# Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Study · id `cardio:ct-nct07034690` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07034690](<https://clinicaltrials.gov/study/NCT07034690>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07034690

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 326 participants.

## Technical summary

Registry record NCT07034690. Randomized; no masking; primary purpose other. Start 2025-11-26 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 326 participants (planned count; ClinicalTrials.gov record NCT07034690, source copy `cardio:ctgov-nct07034690-2026-05-04`, retrieved 2026-10-31)
- Started: 2025-11-26 (actual) (ClinicalTrials.gov record NCT07034690, source copy `cardio:ctgov-nct07034690-2026-05-04`, retrieved 2026-10-31)
- Primary completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT07034690, source copy `cardio:ctgov-nct07034690-2026-05-04`, retrieved 2026-10-31)
- Completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT07034690, source copy `cardio:ctgov-nct07034690-2026-05-04`, retrieved 2026-10-31)
- Countries: United Arab Emirates (ClinicalTrials.gov record NCT07034690, source copy `cardio:ctgov-nct07034690-2026-05-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07034690-2026-05-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
- Acronym: OPTIMA
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Other): Educational Material
- Intervention (Other): Standard of care
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: b58660518cf192c739ca213e810936d85e71fa2ff0906a02d3b6fd83013f3c63
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
